Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
Authors
Arsany Hakim (ORCID: https://orcid.org/0000-0001-9431-1069)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Universitair Ziekenhuis Gent
Jichi Medical University
KU Leuven
Schweizerische Herzstiftung
Universiteit Gent
Gottfried und Julia Bangerter-Rhyner-Stiftung
Université de Lausanne
Centre Hospitalier Universitaire Vaudois
Universiteit Antwerpen
European Academy of Neurology
Kansai Medical University
European Stroke Organisation
Faculty of Medicine and Health, University of Sydney
Daiichi Sankyo Europe
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
Arsany Hakim, Urs Fischer, Takenobu Kunieda, Martina Goeldlin et al.
Citations
2 citations
Journal
Stroke
Topics
Acute Ischemic Stroke Management
Field-Weighted Citation Impact (FWCI)
2.71
article
Prior Reperfusion Strategy Does Not Modify Outcome in Early Versus Late Start of Anticoagulants in Patients With Ischemic Stroke: Prespecified Subanalysis of the Randomized Controlled ELAN Trial
Arsany Hakim, Urs Fischer, Takenobu Kunieda, Martina Goeldlin, Kosuke Matsuzono, Caterina Kulyk, Laetitia Yperzeele, Jan Vynckier, Kanta Tanaka, Jelle Demeestere, Matthieu Pierre Rutgers, Annemie Devroye, Robin Lemmens, Jean‐Benoît Rossel, Alexander Salerno, Gerli Sibolt, Anke Wouters, Dimitri Hemelsoet, Peter Slade, Jesse Dawson, Stefanie Abend, Takeshi Yoshimoto, Peter Vanacker, Jochen Vehoff, Roman Rohner, André Peeters, Philippe Desfontaines
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
StrokeVol. 56(8)
Institutions
University of Bern (CH), Johannes Kepler University of Linz (AT), Kansai Medical University (JP), Bern University of Applied Sciences (CH), Allen Institute for Brain Science (US), Cliniques Universitaires Saint-Luc (BE), University of Helsinki (FI), Jichi Medical University (JP), University of Antwerp (BE), University of St.Gallen (CH), AZ Groeninge (BE), Helsinki University Hospital (FI), University Hospital of Bern (CH), Ghent University Hospital (BE), Morriston Hospital (GB), University Hospital of Basel (CH), Centre Hospitalier Chrétien (BE), Europe Hospitals (BE), Onze Lieve Vrouwziekenhuis Hospital (BE), Antwerp University Hospital (BE), National Cerebral and Cardiovascular Center (JP), Kepler Universitätsklinikum (AT), Queen Elizabeth University Hospital (GB), University of Lausanne (CH), KU Leuven (BE)
Funders
National Science Foundation, Bristol-Myers Squibb, Pfizer, AstraZeneca, Biogen, Alexion Pharmaceuticals, Université Catholique de Louvain, Helsingin Yliopisto, Stryker, University of Bern, Schweizerischen Neurologischen Gesellschaft, National Cerebral and Cardiovascular Center, Inselspital, Universitätsspital Bern, Insel Gruppe, Kepler Universitätsklinikum, University of Glasgow, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Universitair Ziekenhuis Gent, Jichi Medical University, KU Leuven, Schweizerische Herzstiftung, Universiteit Gent, Gottfried und Julia Bangerter-Rhyner-Stiftung, Université de Lausanne, Centre Hospitalier Universitaire Vaudois, Universiteit Antwerpen, European Academy of Neurology, Kansai Medical University, European Stroke Organisation, Faculty of Medicine and Health, University of Sydney, Daiichi Sankyo Europe